Author:
Wensing Annemarie M. J.,Fun Axel,Nijhuis Monique
Reference195 articles.
1. Abecasis AB, Deforche K, Snoeck J et al (2005) Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19(16):1799–1806
2. Abecasis AB, Deforche K, Bacheler LT et al (2006) Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther 11(5):581–589
3. Agniswamy J, Sayer JM, Weber IT, Louis JM (2012) Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease. Biochemistry 51(5):1041–1050
4. Amiel C, Charpentier C, Désiré N et al (2011) Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene. HIV Med 12(3):138–144
5. Arastéh K, Yeni P, Pozniak A et al (2009) Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 14(6):859–864
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献